Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
BIOTEST AG |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 31 EUR | -0.64% | -1.90% | -8.82% | |
| Sales 2023 * | 568M 614M | Sales 2024 * | 636M 687M | Capitalization | 1.46B 1.57B |
|---|---|---|---|---|---|
| Net income 2023 * | -74M -79.98M | Net income 2024 * | -4M -4.32M | EV / Sales 2023 * | 3,65x |
| Net Debt 2023 * | 615M 664M | Net Debt 2024 * | 661M 714M | EV / Sales 2024 * | 3,33x |
| P/E ratio 2023 * | -16,6x | P/E ratio 2024 * | -306x | Employees | 2,228 |
| Yield 2023 * | 0,06% | Yield 2024 * | 0,06% | Free-Float | 29.83% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.32% | ||
| 1 week | -0.64% | ||
| Current month | -0.64% | ||
| 3 months | -0.64% | ||
| 6 months | -1.27% | ||
| Current year | -8.24% |
1 week
31.00
31.80
1 month
30.6031.80
Current year
29.6034.50
1 year
29.6034.80
3 years
25.2044.50
5 years
17.0044.50
10 years
10.3144.50
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 201 M€ | +11.07% | - | |
| 0.00% | 204 M€ | +6.44% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-05 | 31 | -0.64% | 635 |
| 23-12-04 | 31.2 | -0.64% | 125 |
| 23-12-01 | 31.4 | 0.00% | 31 |
| 23-11-30 | 31.4 | +0.64% | 618 |
| 23-11-29 | 31.2 | -1.27% | 996 |
Delayed Quote Xetra, December 04, 2023 at 11:36 am EST
More quotes
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
Sector
Pharmaceuticals
Calendar
2024-03-20
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
31.2EUR
Average target price
37EUR
Spread / Average Target
+18.59%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.24% | 1 576 M $ | |
| -8.56% | 84 465 M $ | |
| -13.28% | 38 718 M $ | |
| -15.91% | 33 740 M $ | |
| -49.54% | 18 046 M $ | |
| +7.71% | 21 257 M $ | |
| -8.78% | 17 782 M $ | |
| -0.41% | 15 316 M $ | |
| -31.57% | 12 317 M $ | |
| +23.28% | 8 738 M $ |
